Our amicus brief supporting en banc review of the court’s Open Internet Order decision
Last week the International Center for Law & Economics and I filed an amicus brief in the DC Circuit in support of en banc review of the court’s . . .
Our amicus brief supporting en banc review of the court’s Open Internet Order decision
Everything is amazing — and no one at the European Commission is happy
Since the European Commission (EC) announced its first inquiry into Google’s business practices in 2010, the company has been the subject of lengthy investigations by . . .
The America Invents Act, a First-to-Invent Patent System, and “Obama-Birther” Accusations
About a month ago, I was asked by some friends about the shift from the first-to-invent patent system to a first-to-file patent system in the . . .
Critics of health insurance mergers misapply the evidence and misinterpret the market
As regulatory review of the merger between Aetna and Humana hits the homestretch, merger critics have become increasingly vocal in their opposition to the deal. . . .
Senate Bill Provides Remedy for Regulatory Abuse Keeping Generics Off the Market
I’d like to begin by discussing Geoff’s post on the pending legislative proposals designed to combat strategic abuse of drug safety regulations to prevent generic competition. Specifically, . . .
Senator Lee’s prescription for regulatory failure in the generic drug market
Brand drug manufacturers are no strangers to antitrust accusations when it comes to their complicated relationship with generic competitors — most obviously with respect to . . .
Congressional testimony on legislative reform proposals for the FTC
Earlier this week I testified before the U.S. House Subcommittee on Commerce, Manufacturing, and Trade regarding several proposed FTC reform bills. You can find my . . .
Level Heads Continue to Prevail: MPAA to be a “Trusted Notifier” With Radix
As we noted in our issue brief on the impending ICANN transition, given the vast scope of the problem, voluntary relationships between registries, registrars and . . .
Trade Secret Protection Gets a Federal Shot in the Arm
Trade secrets are frequently one of the most powerful forms of intellectual property that a company has in its competitive arsenal. Particularly given the ongoing . . .